Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 5 (May)

1. Advanced chemoresistant breast cancer responding to multidisciplinary treatment with hyperthermia, radiotherapy, and intraarterial infusion.
   Int J Clin Oncol, 10(2): 139-43. [Abstract] [Full-text]
2. Intracellular signaling in the induction of apoptosis in a human breast cancer cell line by water extract of Mekabu.
   Int J Clin Oncol, 10(2): 122-6. [Abstract] [Full-text]
3. Mammary ductoscopy: past, present, and future.
   Int J Clin Oncol, 10(2): 112-6. [Abstract] [Full-text]
4. A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma.
   Cytokine, 30(4): 182-7. [Abstract] [Full-text]
5. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial.
   Lancet Oncol, 6(5): 287-94. [Abstract] [Full-text]
6. Retinoids suppress premalignant MCF10AT but not malignant MCF10CA1a breast epithelial cells in vivo. Role of retinoic acid receptor beta2 expression.
   Cancer Lett, 222(2): 153-63. [Abstract] [Full-text]
7. Endothelins in breast tumour cell invasion.
   Cancer Lett, 222(2): 129-38. [Abstract] [Full-text]
8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
   Gynecol Oncol, 97(2): 457-67. [Abstract] [Full-text]
9. Comparative genomic hybridization in four angiosarcomas of the female breast.
   Gynecol Oncol, 97(2): 348-52. [Abstract] [Full-text]
10. Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates.
    J Steroid Biochem Mol Biol, 94(1): 239-51. [Abstract] [Full-text]
11. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.
    J Steroid Biochem Mol Biol, 94(1): 219-27. [Abstract] [Full-text]
12. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.
    J Steroid Biochem Mol Biol, 94(1): 131-41. [Abstract] [Full-text]
13. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators.
    Steroids, 70(5): 418-26. [Abstract] [Full-text]
14. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
    Steroids, 70(5): 372-81. [Abstract] [Full-text]
15. Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines.
    Eur J Cancer, 41(7): 1086-94. [Abstract] [Full-text]
16. In situ breast cancer: incidence trend and organised screening programmes in Italy.
    Eur J Cancer, 41(7): 1045-50. [Abstract] [Full-text]
17. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome.
    Eur J Cancer, 41(7): 1017-25. [Abstract] [Full-text]
18. Breast cancer survivors accurately reported key treatment and prognostic characteristics.
    J Clin Epidemiol, 58(4): 364-9. [Abstract] [Full-text]
19. Combination glutathione and anthocyanins as an alternative for skin care during external-beam radiation.
    Am J Surg, 189(5): 627-30; discussion 630-1. [Abstract] [Full-text]
20. Breast fine-needle aspirates with scant cellularity are clinically useful.
    Am J Surg, 189(5): 621-5; discussion 625-6. [Abstract] [Full-text]
21. Geographic variation in sentinel node adaptation by practicing surgeons in Oregon.
    Am J Surg, 189(5): 616-9; discussion 619-20. [Abstract] [Full-text]
22. Risk counseling and management in patients with lobular carcinoma in situ.
    Am J Surg, 189(5): 610-4; discussion 614-5. [Abstract] [Full-text]
23. The association of cytokeratin-only-positive sentinel lymph nodes and subsequent metastases in breast cancer.
    Am J Surg, 189(5): 606-9; discussion 609. [Abstract] [Full-text]
24. A practical approach to intraoperative evaluation of sentinel lymph node biopsy in breast carcinoma and review of the current methods.
    Ann Surg Oncol, 12(4): 313-21. [Abstract] [Full-text]
25. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
    Oncology, 68(1): 71-8. [Abstract] [Full-text]
26. A retrospective series of long-term survivors of metastatic breast cancer in complete remission.
    Oncology, 68(1): 48-51. [Abstract] [Full-text]
27. Association of regular aspirin use and breast cancer risk.
    Oncology, 68(1): 40-7. [Abstract] [Full-text]
28. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.
    Virchows Arch, 446(4): 442-50. [Abstract] [Full-text]
29. Benign breast lesions in adolescent girls: an overview with a case report.
    Pediatr Surg Int, 21(5): 381-2. [Abstract] [Full-text]
30. Transient transfection of epidermal growth factor receptor gene into MCF7 breast ductal carcinoma cell line.
    Cell Biochem Funct, 23(3): 157-61. [Abstract] [Full-text]
31. Depression and the use of complementary medicine among breast cancer patients.
    Support Care Cancer, 13(5): 339-42. [Abstract] [Full-text]
32. Regional variations in breast cancer incidence among California women, 1988-1997.
    Cancer Causes Control, 16(2): 139-50. [Abstract] [Full-text]
33. Towards a dietary prevention of hereditary breast cancer.
    Cancer Causes Control, 16(2): 125-38. [Abstract] [Full-text]
34. What do cancer survivors believe causes cancer? (United States).
    Cancer Causes Control, 16(2): 115-23. [Abstract] [Full-text]
35. Cancer-specific beliefs and survival: a population-based study of African-American and White breast cancer patients.
    Cancer Causes Control, 16(2): 105-14. [Abstract] [Full-text]
36. A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes.
    Breast Cancer Res Treat, 91(2): 203-5. [Abstract] [Full-text]
37. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Breast Cancer Res Treat, 91(2): 187-201. [Abstract] [Full-text]
38. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
    Breast Cancer Res Treat, 91(2): 179-86. [Abstract] [Full-text]
39. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
    Breast Cancer Res Treat, 91(2): 173-8. [Abstract] [Full-text]
40. Immune dysfunction and micrometastases in women with breast cancer.
    Breast Cancer Res Treat, 91(2): 163-71. [Abstract] [Full-text]
41. Economic outcomes of breast cancer survivorship: CALGB study 79804.
    Breast Cancer Res Treat, 91(2): 153-61. [Abstract] [Full-text]
42. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.
    Breast Cancer Res Treat, 91(2): 145-51. [Abstract] [Full-text]
43. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
    Breast Cancer Res Treat, 91(2): 133-44. [Abstract] [Full-text]
44. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer.
    Breast Cancer Res Treat, 91(2): 125-32. [Abstract] [Full-text]
45. Estimating the number of rate limiting genomic changes for human breast cancer.
    Breast Cancer Res Treat, 91(2): 121-4. [Abstract] [Full-text]
46. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement.
    Breast Cancer Res Treat, 91(2): 113-9. [Abstract] [Full-text]
47. Frequent down-regulation of HIVEP2 in human breast cancer.
    Breast Cancer Res Treat, 91(2): 103-12. [Abstract] [Full-text]
48. Sex cycle modulates cancer growth.
    Breast Cancer Res Treat, 91(1): 95-102. [Abstract] [Full-text]
49. Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Comet-FISH.
    Breast Cancer Res Treat, 91(1): 89-93. [Abstract] [Full-text]
50. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Breast Cancer Res Treat, 91(1): 81-7. [Abstract] [Full-text]
51. MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study.
    Breast Cancer Res Treat, 91(1): 73-9. [Abstract] [Full-text]
52. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
    Breast Cancer Res Treat, 91(1): 61-71. [Abstract] [Full-text]
53. Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation.
    Breast Cancer Res Treat, 91(1): 35-45. [Abstract] [Full-text]
54. Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy.
    Breast Cancer Res Treat, 91(1): 19-28. [Abstract] [Full-text]
55. Effect of axillary lymphadenectomy on breast carcinoma survival.
    Breast Cancer Res Treat, 91(1): 11-8. [Abstract] [Full-text]
56. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res Treat, 91(1): 1-10. [Abstract] [Full-text]
57. Phase II trial of dolastatin-10 in patients with advanced breast cancer.
    Invest New Drugs, 23(3): 257-61. [Abstract] [Full-text]
58. Elucidation of thioredoxin as a molecular target for antitumor quinols.
    Cancer Res, 65(9): 3911-9. [Abstract] [Full-text]
59. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.
    Cancer Res, 65(9): 3903-10. [Abstract] [Full-text]
60. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
    Cancer Res, 65(9): 3861-7. [Abstract] [Full-text]
61. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.
    Cancer Res, 65(9): 3815-22. [Abstract] [Full-text]
62. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas.
    Cancer Res, 65(9): 3796-805. [Abstract] [Full-text]
63. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.
    Cancer Res, 65(9): 3586-95. [Abstract] [Full-text]
64. Autocrine metabolism of vitamin D in normal and malignant breast tissue.
    Clin Cancer Res, 11(9): 3579-86. [Abstract] [Full-text]
65. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
    Clin Cancer Res, 11(9): 3369-76. [Abstract] [Full-text]
66. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Clin Cancer Res, 11(9): 3315-9. [Abstract] [Full-text]
67. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
    Clin Cancer Res, 11(9): 3309-14. [Abstract] [Full-text]
68. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.
    Clin Cancer Res, 11(9): 3184-90. [Abstract] [Full-text]
69. Increased estrogen receptor betacx expression during mammary carcinogenesis.
    Clin Cancer Res, 11(9): 3170-4. [Abstract] [Full-text]
70. Estradiol and medroxyprogesterone acetate regulated genes in T47D breast cancer cells.
    Mol Cell Endocrinol, 235(1): 39-50. [Abstract] [Full-text]
71. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
    Mol Cell Endocrinol, 235(1): 21-9. [Abstract] [Full-text]
72. Ovarian cysts in tamoxifen-treated women with breast cancer.
    Eur J Obstet Gynecol Reprod Biol, 120(1): 104-6. [Abstract] [Full-text]
73. The multifunctional role of the immunohistochemical expression of MMP-7 in invasive breast cancer.
    APMIS, 113(4): 246-55. [Abstract] [Full-text]
74. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells.
    J Biol Chem, 280(18): 17617-25. [Abstract] [Full-text]
75. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer.
    J Biol Chem, 280(18): 18302-10. [Abstract] [Full-text]
76. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
    J Natl Cancer Inst, 97(9): 632-42. [Abstract] [Full-text]
77. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review.
    Am J Epidemiol, 161(10): 901-15. [Abstract] [Full-text]
78. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
    Br J Cancer, 92(9): 1621-5. [Abstract] [Full-text]
79. Myocardial infarction risk and tamoxifen therapy for breast cancer.
    Br J Cancer, 92(9): 1614-20. [Abstract] [Full-text]
80. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ.
    Br J Cancer, 92(9): 1720-8. [Abstract] [Full-text]
81. Intraoperative findings of cancer in delayed breast reconstruction: a dilemma?
    Aesthetic Plast Surg, 28(6): 399-400. [Abstract] [Full-text]
82. Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer.
    J Cell Physiol, 204(1): 106-12. [Abstract] [Full-text]
83. A case report of prefilled polysaccharide hydrogel breast implant rupture: clinical, MRI, and pathologic findings.
    Aesthetic Plast Surg, 28(6): 401-4. [Abstract] [Full-text]
84. Lipid-rich carcinoma of the mammary gland in a cat.
    Vet Pathol, 42(3): 360-2. [Abstract] [Full-text]
85. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry.
    J Histochem Cytochem, 53(5): 621-9. [Abstract] [Full-text]
86. Vascular endothelial growth factor mRNA levels quantified by reverse transcription-polymerase chain reaction in microdissected breast carcinoma tissues are correlated with histological type and grade of both invasive and intraductal components.
    Pathol Int, 55(5): 255-63. [Abstract] [Full-text]
87. The value of FDG positron emission tomography in the management of patients with breast cancer.
    Breast J, 11(3): 204-9. [Abstract] [Full-text]
88. Postlumpectomy Insertion of the MammoSite brachytherapy device using the scar entry technique: initial experience and technical considerations.
    Breast J, 11(3): 199-203. [Abstract] [Full-text]
89. Cosmesis with bilateral mammoreduction for conservative breast cancer treatment.
    Breast J, 11(3): 195-8. [Abstract] [Full-text]
90. Effect of lymphatic tumor burden on sentinel lymph node biopsy in breast cancer.
    Breast J, 11(3): 188-94. [Abstract] [Full-text]
91. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
    Breast J, 11(3): 183-7. [Abstract] [Full-text]
92. The influence of knowledge of mammography findings on the accuracy of breast ultrasound in symptomatic women.
    Breast J, 11(3): 167-72. [Abstract] [Full-text]
93. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis.
    Nat Med, 11(5): 481-3. [Abstract] [Full-text]
94. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
    Cancer, 103(10): 2199-207. [Abstract] [Full-text]
95. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
    Cancer, 103(10): 1996-2005. [Abstract] [Full-text]
96. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
    Cancer, 103(10): 2006-14. [Abstract] [Full-text]
97. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Cancer Chemother Pharmacol, 56(1): 46-54. [Abstract] [Full-text]
98. Accumulation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells.
    Oncogene, 24(20): 3369-76. [Abstract] [Full-text]
99. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.
    J Clin Endocrinol Metab, 90(5): 2563-70. [Abstract] [Full-text]
100. Application of the compound probability density function for characterization of breast masses in ultrasound B scans.
     Phys Med Biol, 50(10): 2241-8. [Abstract] [Full-text]
101. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
     J Steroid Biochem Mol Biol, 94(5): 461-7. [Abstract] [Full-text]
102. Anti-growth factor activities of benzothiophenes in human breast cancer cells.
     J Steroid Biochem Mol Biol, 94(5): 451-60. [Abstract] [Full-text]
103. Combinatory effects of phytoestrogens and 17beta-estradiol on proliferation and apoptosis in MCF-7 breast cancer cells.
     J Steroid Biochem Mol Biol, 94(5): 445-9. [Abstract] [Full-text]
104. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells.
     J Steroid Biochem Mol Biol, 94(5): 431-43. [Abstract] [Full-text]
105. Targeting of therapeutic agents to bone to treat metastatic cancer.
     Adv Drug Deliv Rev, 57(7): 995-1010. [Abstract] [Full-text]
106. Selective exposure reporting and Medline indexing limited the search sensitivity for observational studies of the adverse effects of oral contraceptives.
     J Clin Epidemiol, 58(6): 560-7. [Abstract] [Full-text]
107. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.
     Exp Cell Res, 306(1): 128-41. [Abstract] [Full-text]
108. Reliability of portal control procedure in irradiation of breast cancer: a Bayesian analysis.
     Radiother Oncol, 75(1): 28-33. [Abstract] [Full-text]
109. Evaluation of set-up deviations during the irradiation of patients suffering from breast cancer treated with two different techniques.
     Radiother Oncol, 75(1): 22-7. [Abstract] [Full-text]
110. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer.
     Radiother Oncol, 75(1): 18-21. [Abstract] [Full-text]
111. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial.
     Radiother Oncol, 75(1): 9-17. [Abstract] [Full-text]
112. Reduced mammographic screening may explain declines in breast carcinoma in older women.
     J Am Geriatr Soc, 53(5): 862-6. [Abstract] [Full-text]
113. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families.
     Genes Chromosomes Cancer, 43(3): 309-13. [Abstract] [Full-text]
114. Competition on nitrocellulose-immobilized antibody arrays: from bacterial protein binding assay to protein profiling in breast cancer cells.
     Mol Cell Proteomics, 4(5): 605-17. [Abstract] [Full-text]
115. Meaning in life and psycho-spiritual functioning: a comparison of breast cancer survivors and healthy women.
     J Holist Nurs, 23(2): 172-90. [Abstract] [Full-text]
116. Spiritual struggle: effect on quality of life and life satisfaction in women with breast cancer.
     J Holist Nurs, 23(2): 120-40; discussion 141-4. [Abstract] [Full-text]
117. Biomedical and psychosocial determinants of intrusive recollections in breast cancer survivors.
     Psychosomatics, 46(3): 203-11. [Abstract] [Full-text]
118. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.
     Cell, 121(3): 335-48. [Abstract] [Full-text]
119. Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
     Scand J Immunol, 61(5): 449-60. [Abstract] [Full-text]
120. Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer.
     J Pathol, 206(2): 220-3. [Abstract] [Full-text]
121. Resveratrol and breast cancer chemoprevention: molecular mechanisms.
     Mol Nutr Food Res, 49(5): 462-71. [Abstract] [Full-text]
122. Dietary factors modifying breast cancer risk and relation to time of intake.
     J Mammary Gland Biol Neoplasia, 10(1): 87-100. [Abstract] [Full-text]
123. Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia.
     J Mammary Gland Biol Neoplasia, 10(1): 75-86. [Abstract] [Full-text]
124. Pregnancy and stem cell behavior.
     J Mammary Gland Biol Neoplasia, 10(1): 25-36. [Abstract] [Full-text]
125. Stem/progenitor cells in mouse mammary gland development and breast cancer.
     J Mammary Gland Biol Neoplasia, 10(1): 17-24. [Abstract] [Full-text]
126. Brief report: etiological attributions for breast cancer among healthy African American and European American women.
     Psychooncology, 14(5): 421-5. [Abstract] [Full-text]
127. Conceptualization and sources of costs from breast cancer: findings from patient and caregiver focus groups.
     Psychooncology, 14(5): 351-60. [Abstract] [Full-text]
128. Psychosocial impact of newly diagnosed advanced breast cancer.
     Psychooncology, 14(5): 396-407. [Abstract] [Full-text]
129. Video preparation for breast cancer treatment planning: results of a randomized clinical trial.
     Psychooncology, 14(5): 408-20. [Abstract] [Full-text]
130. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
     Hum Pathol, 36(4): 348-56. [Abstract] [Full-text]
131. A multicultural and multilingual outreach program for cervical and breast cancer screening.
     J Obstet Gynecol Neonatal Nurs, 34(3): 395-402. [Abstract] [Full-text]
132. Factors influencing mammography screening of Chinese American women.
     J Obstet Gynecol Neonatal Nurs, 34(3): 386-94. [Abstract] [Full-text]
133. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?
     Int J Radiat Oncol Biol Phys, 62(2): 386-91. [Abstract] [Full-text]
134. Breast-conserving therapy in patients with bilateral breast cancer: do today's treatment choices burn bridges for tomorrow?
     Int J Radiat Oncol Biol Phys, 62(2): 379-85. [Abstract] [Full-text]
135. Analysis of interfraction and intrafraction variation during tangential breast irradiation with an electronic portal imaging device.
     Int J Radiat Oncol Biol Phys, 62(2): 373-8. [Abstract] [Full-text]
136. Surface optimization technique for MammoSite breast brachytherapy applicator.
     Int J Radiat Oncol Biol Phys, 62(2): 366-72. [Abstract] [Full-text]
137. A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations.
     Int J Radiat Oncol Biol Phys, 62(2): 358-65. [Abstract] [Full-text]
138. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
     Int J Radiat Oncol Biol Phys, 62(2): 351-7. [Abstract] [Full-text]
139. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer.
     Cancer Lett, 223(1): 143-50. [Abstract] [Full-text]
140. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer.
     Cancer Lett, 223(1): 113-9. [Abstract] [Full-text]
141. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
     Cancer Lett, 223(1): 103-11. [Abstract] [Full-text]
142. Associated nutritional risk of breast and colon cancers: a population-based case-control study in Montreal, Canada.
     Cancer Lett, 223(1): 85-91. [Abstract] [Full-text]
143. Extremely indirect dermal lymphatic channels: value of areolar-cutaneous junction injection technique for breast lymphoscintigraphy.
     Curr Surg, 62(3): 335-7. [Abstract] [Full-text]
144. Differential susceptibility of nonmalignant human breast epithelial cells and breast cancer cells to thiol antioxidant-induced G(1)-delay.
     Antioxid Redox Signal, 7(5): 711-8. [Abstract] [Full-text]
145. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer.
     Oncogene, 24(21): 3448-58. [Abstract] [Full-text]
146. Intraoperative ultrasound-guided excision of nonpalpable breast lesions.
     World J Surg, 29(3): 369-74. [Abstract] [Full-text]
147. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
     Womens Health Issues, 15(3): 97-108. [Abstract] [Full-text]
148. Evaluation of radiological features for breast tumour classification in clinical screening with machine learning methods.
     Artif Intell Med, 34(2): 129-39. [Abstract] [Full-text]
149. Predicting breast cancer survivability: a comparison of three data mining methods.
     Artif Intell Med, 34(2): 113-27. [Abstract] [Full-text]
150. Breast cancer.
     Lancet, 365(9472): 1727-41. [Abstract] [Full-text]
151. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
     Lancet, 365(9472): 1687-717. [Abstract] [Full-text]
152. Optimization of conformal avoidance: a comparative study of prone vs. supine interstitial high-dose-rate breast brachytherapy.
     Brachytherapy, 4(2): 137-40. [Abstract] [Full-text]
153. The MammoSite breast brachytherapy applicator: a review of technique and outcomes.
     Brachytherapy, 4(2): 130-6. [Abstract] [Full-text]
154. Accelerated partial breast irradiation: a dosimetric comparison of three different techniques.
     Brachytherapy, 4(2): 121-9. [Abstract] [Full-text]
155. Patient-centered care and breast cancer survivors' satisfaction with information.
     Patient Educ Couns, 57(3): 342-9. [Abstract] [Full-text]
156. How making a risk estimate can change the feel of that risk: shifting attitudes toward breast cancer risk in a general public survey.
     Patient Educ Couns, 57(3): 294-9. [Abstract] [Full-text]
157. The decision evaluation scales.
     Patient Educ Couns, 57(3): 286-93. [Abstract] [Full-text]
158. Cadherins and the mammary gland.
     J Cell Biochem, 95(3): 488-96. [Abstract] [Full-text]
159. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology.
     NMR Biomed, 18(3): 173-85. [Abstract] [Full-text]
160. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.
     Clin Cancer Res, 11(10): 3930-8. [Abstract] [Full-text]
161. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
     Clin Cancer Res, 11(10): 3869-78. [Abstract] [Full-text]
162. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer.
     Clin Cancer Res, 11(10): 3828-35. [Abstract] [Full-text]
163. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
     Clin Cancer Res, 11(10): 3722-32. [Abstract] [Full-text]
164. An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer.
     Clin Cancer Res, 11(10): 3697-704. [Abstract] [Full-text]
165. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.
     Clin Cancer Res, 11(10): 3678-85. [Abstract] [Full-text]
166. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.
     Clin Cancer Res, 11(10): 3647-53. [Abstract] [Full-text]
167. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
     Mol Cancer Ther, 4(5): 824-34. [Abstract] [Full-text]
168. Strongylophorine-26, a Rho-dependent inhibitor of tumor cell invasion that reduces actin stress fibers and induces nonpolarized lamellipodial extensions.
     Mol Cancer Ther, 4(5): 772-8. [Abstract] [Full-text]
169. Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins.
     J Dermatolog Treat, 16(1): 19-21. [Abstract] [Full-text]
170. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells.
     Cancer Lett, 223(2): 293-301. [Abstract] [Full-text]
171. Aromatase inhibitors in the treatment of breast cancer.
     Endocr Rev, 26(3): 331-45. [Abstract] [Full-text]
172. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17.
     J Biol Chem, 280(20): 19543-50. [Abstract] [Full-text]
173. CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells.
     J Biol Chem, 280(20): 20086-93. [Abstract] [Full-text]
174. Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1.
     Int J Cancer, 115(5): 760-8. [Abstract] [Full-text]
175. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
     Int J Cancer, 115(5): 783-9. [Abstract] [Full-text]
176. Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer.
     Immunogenetics, 57(3): 165-71. [Abstract] [Full-text]
177. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
     J Natl Cancer Inst, 97(10): 755-65. [Abstract] [Full-text]
178. Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators.
     J Natl Cancer Inst, 97(10): 748-54. [Abstract] [Full-text]
179. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
     JAMA, 293(19): 2367-71. [Abstract] [Full-text]
180. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
     Mol Cell Biol, 25(11): 4703-15. [Abstract] [Full-text]
181. Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells.
     Cancer Res, 65(10): 4442-7. [Abstract] [Full-text]
182. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice.
     Cancer Res, 65(10): 4408-16. [Abstract] [Full-text]
183. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins.
     Cancer Res, 65(10): 4353-61. [Abstract] [Full-text]
184. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells.
     Cancer Res, 65(10): 4273-81. [Abstract] [Full-text]
185. BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis.
     Cancer Res, 65(10): 4117-25. [Abstract] [Full-text]
186. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
     Cancer Res, 65(10): 4101-17. [Abstract] [Full-text]
187. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification.
     Cancer Res, 65(10): 4078-87. [Abstract] [Full-text]
188. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.
     Cancer Res, 65(10): 4059-66. [Abstract] [Full-text]
189. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.
     Am J Clin Pathol, 123(6): 889-95. [Abstract] [Full-text]
190. Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast.
     Am J Clin Pathol, 123(6): 866-73. [Abstract] [Full-text]
191. A comparative study of 2D and 3D ultrasonography for evaluation of solid breast masses.
     Eur J Radiol, 54(3): 365-70. [Abstract] [Full-text]
192. Partner's adjustment to breast cancer: a critical analysis of intervention studies.
     Health Psychol, 24(3): 327-32. [Abstract] [Full-text]
193. Traumatic stress, perceived global stress, and life events: prospectively predicting quality of life in breast cancer patients.
     Health Psychol, 24(3): 288-96. [Abstract] [Full-text]
194. The impact of breast cancer on the lives of middle-aged women: results from the Australian longitudinal study of women's health.
     Health Psychol, 24(3): 246-51. [Abstract] [Full-text]
195. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
     Br J Cancer, 92(10): 1869-76. [Abstract] [Full-text]
196. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
     Br J Cancer, 92(10): 1881-91. [Abstract] [Full-text]
197. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.
     Br J Cancer, 92(10): 1922-6. [Abstract] [Full-text]
198. Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer.
     Br J Cancer, 92(10): 1948-52. [Abstract] [Full-text]
199. Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts.
     Bone Marrow Transplant, 35(11): 1055-64. [Abstract] [Full-text]
200. Post-transcriptional regulation of metallothionein isoform 1 and 2 expression in the human breast and the MCF-10A cell line.
     Toxicol Sci, 85(2): 906-15. [Abstract] [Full-text]
201. Association of common ATM polymorphism with bilateral breast cancer.
     Int J Cancer, 116(1): 69-72. [Abstract] [Full-text]
202. Dietary patterns and the risk of postmenopausal breast cancer.
     Int J Cancer, 116(1): 116-21. [Abstract] [Full-text]
203. Breast cancer services--a population-based study of service reorganization.
     J Public Health (Oxf), 27(2): 171-5. [Abstract] [Full-text]
204. Dietary and other risk factors in women having fibrocystic breast conditions with and without concurrent breast cancer: a nested case-control study in Shanghai, China.
     Int J Cancer, 115(6): 981-93. [Abstract] [Full-text]
205. Optical characterization of thin female breast biopsies based on the reduced scattering coefficient.
     Phys Med Biol, 50(11): 2583-96. [Abstract] [Full-text]
206. Optical biopsy of breast tissue using differential path-length spectroscopy.
     Phys Med Biol, 50(11): 2573-81. [Abstract] [Full-text]
207. The Twente Photoacoustic Mammoscope: system overview and performance.
     Phys Med Biol, 50(11): 2543-57. [Abstract] [Full-text]
208. Time-domain scanning optical mammography: II. Optical properties and tissue parameters of 87 carcinomas.
     Phys Med Biol, 50(11): 2451-68. [Abstract] [Full-text]
209. Time-domain scanning optical mammography: I. Recording and assessment of mammograms of 154 patients.
     Phys Med Biol, 50(11): 2429-49. [Abstract] [Full-text]
210. Hepatic resection for breast cancer metastases.
     Ann R Coll Surg Engl, 87(3): 167-70. [Abstract] [Full-text]
211. Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.
     Eur Radiol, 15(6): 1224-33. [Abstract] [Full-text]
212. Gray scale and power Doppler US in the preoperative evaluation of axillary metastases in breast cancer patients with no palpable lymph nodes.
     Eur Radiol, 15(6): 1215-23. [Abstract] [Full-text]
213. Couples who get closer after breast cancer: frequency and predictors in a prospective investigation.
     J Clin Oncol, 23(15): 3588-96. [Abstract] [Full-text]
214. Home-based physical activity intervention for breast cancer patients.
     J Clin Oncol, 23(15): 3577-87. [Abstract] [Full-text]
215. Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer.
     J Clin Oncol, 23(15): 3455-64. [Abstract] [Full-text]
216. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
     J Clin Oncol, 23(15): 3331-42. [Abstract] [Full-text]
217. Quality of life among younger women with breast cancer.
     J Clin Oncol, 23(15): 3322-30. [Abstract] [Full-text]
218. Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study).
     Ann Oncol, 16(6): 915-22. [Abstract] [Full-text]
219. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.
     Ann Oncol, 16(6): 909-14. [Abstract] [Full-text]
220. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study.
     Ann Oncol, 16(6): 899-908. [Abstract] [Full-text]
221. Progesterone enhances cytokine-stimulated nitric oxide synthase II expression and cell death in human breast cancer cells.
     Lab Invest, 85(5): 624-32. [Abstract] [Full-text]
222. Sentinel node micrometastasis in breast carcinoma may not be an indication for complete axillary dissection.
     Mod Pathol, 18(6): 762-8. [Abstract] [Full-text]
223. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
     J Clin Oncol, 23(15): 3314-21. [Abstract] [Full-text]
224. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy.
     Mod Pathol, 18(5): 615-20. [Abstract] [Full-text]
225. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast.
     Mod Pathol, 18(6): 741-51. [Abstract] [Full-text]
226. Invasive lobular carcinoma: to grade or not to grade.
     Mod Pathol, 18(5): 621-8. [Abstract] [Full-text]
227. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer: a systematic review and meta-analysis.
     Integr Cancer Ther, 4(2): 144-55. [Abstract] [Full-text]
228. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population.
     Eur J Cancer, 41(8): 1164-9. [Abstract] [Full-text]
229. Docetaxel administration schedule: from fever to tears? A review of randomised studies.
     Eur J Cancer, 41(8): 1117-26. [Abstract] [Full-text]
230. Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer.
     Cancer Lett, 224(1): 133-9. [Abstract] [Full-text]
231. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
     Lancet, 365(9473): 1769-78. [Abstract] [Full-text]
232. Ablative therapies for the treatment of malignant diseases of the breast.
     Am J Surg, 189(6): 694-701. [Abstract] [Full-text]
233. In vitro effects of keyhole limpet hemocyanin in breast and pancreatic cancer in regards to cell growth, cytokine production, and apoptosis.
     Am J Surg, 189(6): 680-4. [Abstract] [Full-text]
234. Multiple re-excisions versus mastectomy in patients with persistent residual disease following breast conservation surgery.
     Am J Surg, 189(6): 662-6. [Abstract] [Full-text]
235. Evaluation of sentinel lymph nodes in breast cancer.
     Histopathology, 46(6): 697-702. [Abstract] [Full-text]
236. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
     Histopathology, 46(6): 685-93. [Abstract] [Full-text]
237. Use of a multiseparation fiber optic probe for the optical diagnosis of breast cancer.
     J Biomed Opt, 10(2): 024032. [Abstract] [Full-text]
238. Image analysis systems for the detection of disseminated breast cancer cells on bone-marrow cytospins.
     J Clin Lab Anal, 19(3): 115-9. [Abstract] [Full-text]
239. Polymorphisms in CYP1A1 and breast carcinoma risk in a population-based case-control study of Chinese women.
     Cancer, 103(11): 2228-35. [Abstract] [Full-text]
240. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
     Cancer, 103(11): 2241-51. [Abstract] [Full-text]
241. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
     Cancer, 103(11): 2252-60. [Abstract] [Full-text]
242. Management of suspicious or indeterminate calcifications and impact on local control.
     Cancer, 103(11): 2236-40. [Abstract] [Full-text]
243. Paget's disease of the breast: there is a role for breast-conserving therapy.
     Ann Surg Oncol, 12(5): 391-7. [Abstract] [Full-text]
244. Physical activity and survival after breast cancer diagnosis.
     JAMA, 293(20): 2479-86. [Abstract] [Full-text]
245. Performance benchmarks for diagnostic mammography.
     Radiology, 235(3): 775-90. [Abstract] [Full-text]
246. Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.
     Cancer Lett, 224(2): 221-8. [Abstract] [Full-text]
247. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
     Cancer Lett, 224(2): 185-91. [Abstract] [Full-text]
248. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.
     J Immunol Methods, 299(1): 177-88. [Abstract] [Full-text]
249. An efficient proteomics-based approach for the screening of autoantibodies.
     J Immunol Methods, 299(1): 77-89. [Abstract] [Full-text]
250. Breast MRI findings after modified radical mastectomy and transverse rectus abdominis myocutaneous flap in patients with breast cancer.
     J Magn Reson Imaging, 21(6): 784-91. [Abstract] [Full-text]
251. Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer.
     Proc Natl Acad Sci U S A, 102(21): 7659-64. [Abstract] [Full-text]
252. Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity.
     Radiology, 235(3): 791-7. [Abstract] [Full-text]
253. Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer.
     Radiology, 235(3): 872-8. [Abstract] [Full-text]
254. Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells.
     Mol Endocrinol, 19(6): 1606-17. [Abstract] [Full-text]
255. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells.
     Mol Endocrinol, 19(6): 1584-92. [Abstract] [Full-text]
256. The manufacturer's perspective.
     Br J Radiol, 78: S41-5. [Abstract] [Full-text]
257. Use of computer-aided detection (CAD) tools in screening mammography: a multidisciplinary investigation.
     Br J Radiol, 78: S31-40. [Abstract] [Full-text]
258. Evaluation of computer-aided detection (CAD) devices.
     Br J Radiol, 78: S26-30. [Abstract] [Full-text]
259. Evaluation of computer-aided detection (CAD) prompting techniques for mammography.
     Br J Radiol, 78: S20-5. [Abstract] [Full-text]
260. Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases.
     J Clin Pathol, 58(6): 645-9. [Abstract] [Full-text]
261. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
     J Clin Pathol, 58(6): 611-6. [Abstract] [Full-text]
262. Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour.
     J Clin Pathol, 58(6): 600-4. [Abstract] [Full-text]
263. Expression of ZER6 in ERalpha-positive breast cancer.
     J Surg Res, 126(1): 86-91; discussion 1-2. [Abstract] [Full-text]
264. Setting educational priorities for women's preventive health: measuring beliefs about screening across disease states.
     J Womens Health (Larchmt), 14(4): 324-30. [Abstract] [Full-text]
265. Understanding locally advanced breast cancer: what influences a woman's decision to delay treatment?
     Prev Med, 41(2): 399-405. [Abstract] [Full-text]
266. AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer.
     Oncogene, 24(23): 3759-73. [Abstract] [Full-text]
267. p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis.
     Oncogene, 24(23): 3774-85. [Abstract] [Full-text]
268. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial.
     J Clin Endocrinol Metab, 90(6): 3209-14. [Abstract] [Full-text]
269. Apoptosis and production of TNF-alpha by tumor-associated inflammatory cells in histological grade III breast cancer.
     Cancer Immunol Immunother, 54(7): 671-6. [Abstract] [Full-text]
270. Estimation of the content of fat and parenchyma in breast tissue using MRI T1 histograms and phantoms.
     Magn Reson Imaging, 23(4): 591-9. [Abstract] [Full-text]
271. An improved 1H magnetic resonance spectroscopic imaging technique for the human breast: preliminary results.
     Magn Reson Imaging, 23(4): 571-6. [Abstract] [Full-text]
272. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
     Cell Immunol, 231(1): 112-25. [Abstract] [Full-text]
273. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.
     Nat Genet, 37(6): 590-2. [Abstract] [Full-text]
274. GPCALMA: a Grid-based tool for mammographic screening.
     Methods Inf Med, 44(2): 244-8. [Abstract] [Full-text]
275. A multi-resolution approach for content-based image retrieval on the Grid--application to breast cancer detection.
     Methods Inf Med, 44(2): 211-4. [Abstract] [Full-text]
276. Digital mammography: a world without film?
     Methods Inf Med, 44(2): 168-71. [Abstract] [Full-text]
277. Resolving clinicians' queries across a Grid's infrastructure.
     Methods Inf Med, 44(2): 149-53. [Abstract] [Full-text]
278. Analysis of treatment practices for elderly cancer patients in Ontario, Canada.
     J Clin Oncol, 23(16): 3802-10. [Abstract] [Full-text]
279. Molecular clonality relationships in initial carcinomas, ipsilateral breast failures, and distant metastases in patients treated with breast-conserving therapy: evidence suggesting that some distant metastases are derived from ipsilateral breast failures and that metastases can metastasize.
     Am J Clin Pathol, 124(1): 49-57. [Abstract] [Full-text]
280. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis.
     Am J Clin Pathol, 124(1): 97-102. [Abstract] [Full-text]
281. The prognostic significance of axillary lymph-node micrometastases in breast cancer patients.
     Eur J Surg Oncol, 31(5): 500-5. [Abstract] [Full-text]
282. Post-operative care and patient satisfaction after ambulatory surgery for breast cancer patients.
     Eur J Surg Oncol, 31(5): 495-9. [Abstract] [Full-text]
283. Touch imprint cytology of core needle biopsy specimens: a useful method for immediate reporting of symptomatic breast lesions.
     Eur J Surg Oncol, 31(5): 490-4. [Abstract] [Full-text]
284. Long-term prognosis of patients with axillary recurrence after axillary dissection for invasive breast cancer.
     Eur J Surg Oncol, 31(5): 485-9. [Abstract] [Full-text]
285. Axillary sentinel lymph nodes in breast cancer: a single lymphatic pathway drains the entire mammary gland.
     Eur J Surg Oncol, 31(5): 479-84. [Abstract] [Full-text]
286. The influence of hormone replacement therapy on the pathology of breast cancer.
     Eur J Surg Oncol, 31(5): 467-72. [Abstract] [Full-text]
287. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
     Exp Cell Res, 307(1): 41-51. [Abstract] [Full-text]
288. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
     J Am Coll Surg, 200(6): 912-21. [Abstract] [Full-text]
289. Dosimetric comparison of conventional and forward-planned intensity-modulated techniques for comprehensive locoregional irradiation of post-mastectomy left breast cancers.
     Med Dosim, 30(2): 107-16. [Abstract] [Full-text]